– CNBC
RBC Capital Maintains Outperform on DocuSign, Lowers Price Target to $95
RBC Capital analyst Rishi Jaluria maintains DocuSign (NASDAQ:DOCU) with a Outperform and lowers the price target from $220 to $95.
Related Posts
Procept BioRobotics’ Aquablation Therapy Shows Encouraging Five-Year Data In Prostate Gland Enlargement
Procept BioRobotics Corp (NASDAQ: PRCT)